2021
Levothyroxine Use in the United States, 2008-2018
Brito JP, Ross JS, Kawkgi O, Maraka S, Deng Y, Shah ND, Lipska KJ. Levothyroxine Use in the United States, 2008-2018. JAMA Internal Medicine 2021, 181: 1402-1405. PMID: 34152370, PMCID: PMC8218227, DOI: 10.1001/jamainternmed.2021.2686.Peer-Reviewed Original ResearchPhysician variation in the de‐adoption of ineffective statin and fibrate therapy
Everhart A, Desai NR, Dowd B, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Smith LB, Karaca‐Mandic P. Physician variation in the de‐adoption of ineffective statin and fibrate therapy. Health Services Research 2021, 56: 919-931. PMID: 33569804, PMCID: PMC8522575, DOI: 10.1111/1475-6773.13630.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes Mellitus, Type 2Drug Therapy, CombinationDrug UtilizationFemaleFibric AcidsGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsLongitudinal StudiesMaleMedicare Part CMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Risk FactorsUnited StatesConceptsMedicare Advantage patientsType 2 diabetic patientsACCORD lipid trialFibrate useAdvantage patientsCommercial patientsPhysician characteristicsLIPID trialFibrate therapyDiabetic patientsPhysician variationDiabetes careType 2 diabetes diagnosisContinuous insurance enrollmentPatient diabetes carePhysician random effectsGlucose-lowering drugsElectronic health record dataHealth record dataReal-world data assetConcurrent statinCardiovascular eventsStatin usersClinical evidenceManagement visits
2018
National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults
Rhee TG, Choi YC, Ouellet GM, Ross JS. National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults. Journal Of The American Geriatrics Society 2018, 66: 1382-1387. PMID: 29582410, PMCID: PMC6097908, DOI: 10.1111/jgs.15357.Peer-Reviewed Original ResearchConceptsNational Ambulatory Medical Care SurveyAnticholinergic prescriptionsPhysician specialtyDrug classesPrescribing trendsOffice-based outpatient visitsOffice-based physician visitsAmbulatory Medical Care SurveyMultivariable logistic regression analysisOlder adultsNational prescribing trendsCommon drug classesLogistic regression analysisCross-sectional analysisSpecific physician specialtiesAnticholinergic medicationsPhysician visitsOutpatient visitsQuality prescribingCare SurveyFemale sexStratified analysisSouthern geographic regionsGreater oddsTotal visits
2017
Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015.
Samuels EA, Ross JS, Dhruva SS. Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015. Annals Of Internal Medicine 2017, 167: 895-896. PMID: 29052693, DOI: 10.7326/m17-1823.Peer-Reviewed Original ResearchTrends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 1568-1577.e4. PMID: 28958746, DOI: 10.1016/j.jaip.2017.07.034.Peer-Reviewed Original ResearchConceptsOmalizumab initiationAsthma controlICS-LABAPatient selectionLow adherenceBetter asthma controlCohort of nonusersSuboptimal patient selectionPoor asthma controlLow adherence ratesPatient-level characteristicsLarge US databaseMedicare Advantage beneficiariesAsthma biologicsExacerbation frequencyOmalizumab useIncident useComparison cohortICS/Medication adherenceAdherence ratesPrevalent usersAdministrative claimsAsthmaUtilization trends
2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medicationsTrends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinLogistic ModelsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsThiazolidinedionesYoung AdultConceptsGlycemic controlSevere hypoglycemiaOlder patientsDipeptidyl peptidase-4 inhibitorsGlucose-lowering drugsGlucose-lowering medicationsProportion of patientsOverall glycemic controlPeptidase-4 inhibitorsMedicare Advantage patientsSex-standardized ratesType 2 diabetesOverall rateClass of agentsMore comorbiditiesChronic comorbiditiesYounger patientsAdvantage patientsDrug utilizationClaims dataPatientsHypoglycemiaHemoglobin AT2DMComorbidities
2008
Use of Ezetimibe in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsLow-density lipoprotein cholesterolLipid-lowering guidelinesRatio of prescriptionsUse of ezetimibeTreatment of hyperlipidemiaStatin useCohort studyLipoprotein cholesterolSecondary preventionStatin prescriptionClinical outcomesPrescribing practicesEzetimibeIMS HealthUnited StatesPrescriptionMonthly numberFirst optionDistinct patterns